DSL 202
Alternative Names: DSL-202Latest Information Update: 06 Apr 2026
At a glance
- Originator DSciLab
- Class Cardiovascular therapies; RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiomyopathies
Most Recent Events
- 17 Mar 2026 Preclinical trials in Cardiomyopathies in China (Parenteral) (DSciLab pipeline, March 2026)